Radiotherapy-induced Nausea and Vomiting

Kristopher Dennis; Ernesto Maranzano; Carlo De Angelis; Lori Holden; Shun Wong; Edward Chow


Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(6):685-692. 

In This Article

Five-year View

We believe that a small group of interested international investigators will emerge to coordinate future research goals in RINV. In the absence of abundant industry research support, the number of key study concepts will necessarily be small, and their designs will need to be pragmatic and based on high-quality Phase I and II trials carried out within a network of individual institutions. However, with an efficient organizational structure, in 5 years it is likely that a new generation of observational studies will have better defined the risks of RINV in less-studied anatomical sites such as the brain, thorax and pelvis, and that dosimetric variables predictive of RINV for most sites will be known. All of this will be aided by the creation and promotion of a consensus statement on recommended end points and reporting styles that all future studies in RINV should employ. This common language for antiemetic research will also allow re-evaluations of data from previous trials in RINV to better appreciate the relative efficacy of different antiemetic regimens. Finally, by raising awareness of RINV as common clinical concerns, and educating patients about their options for prevention, a strong patient interest and advocacy movement will develop, and this will ultimately be the most powerful motivator for progress in this field.